Pacira BioSciences, Inc. PCRX Business Segments — Stock-Based Comp
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Pacira BioSciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The official record: Pacira BioSciences, Inc.’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Pacira BioSciences, Inc.'s business segments — stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Pacira BioSciences, Inc.'s business segments — stock-based comp?
- Pacira BioSciences, Inc. (PCRX) reported business segments — stock-based comp of $13.54M in Q1 2026.
- How has Pacira BioSciences, Inc.'s business segments — stock-based comp changed year-over-year?
- Pacira BioSciences, Inc.'s business segments — stock-based comp decreased by 7.0% year-over-year, from $14.55M to $13.54M.
- What is the long-term trend for Pacira BioSciences, Inc.'s business segments — stock-based comp?
- Over 3 years (2022 to 2025), Pacira BioSciences, Inc.'s business segments — stock-based comp has grown at a 6.1% compound annual growth rate (CAGR), from $48.09M to $57.5M.
- What does business segments — stock-based comp mean?
- Measures the non-cash expense recognized for equity-based awards granted to employees within the reportable segment. It is a critical component of total compensation and reflects the cost of aligning employee incentives with shareholder interests.